Sung-Soo Yoon

Publications726
h-index44
Citations11,565
Highly Influential Citations434
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Dimopoulos
  • 2,074 Publications • 76,080 Citations
  • P. Richardson
  • 1,690 Publications • 102,239 Citations
  • P. Moreau
  • 1,530 Publications • 65,143 Citations
  • H. Kantarjian
  • 4,838 Publications • 221,792 Citations
  • Publications
  • Influence
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
TLDR
The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Integrated molecular analysis of adult T cell leukemia/lymphoma
TLDR
The identified alterations overlap significantly with the HTLV-1 Tax interactome and are highly enriched for T cell receptor–NF-κB signaling, T cell trafficking and other T cell–related pathways as well as immunosurveillance.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
TLDR
In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised,…
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
TLDR
Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
TLDR
Among patients with newly diagnosed multiple myeloma who were ineligible for stem‐cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without darumumab.
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and…
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
TLDR
The combination of nilotinib with high-dose cytotoxic drugs was feasible, and it effectively achieved high cumulative complete molecular remission and HRFS rates.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Patterns of somatic structural variation in human cancer genomes
TLDR
Whole-genome sequencing data from more than 2,500 cancers of 38 tumour types reveal 16 signatures that can be used to classify somatic structural variants, highlighting the diversity of genomic rearrangements in cancer.
...
1
2
3
4
5
...